Research Article : J Ocul Infect Inflamm 2018, Vol 2(1): 105
Received Date: Feb 11, 2018 / Accepted Date: Mar 12, 2018 / Published Date: Mar 16, 2018
Purpose: To determine whether nepafenac ophthalmic suspension 0.3% in co-administration with dexamethasone 0.1%, effectively reduces the incidence of Irvine-Gass syndrome, after uneventful cataract surgery.
Setting: Laserlens One Day Clinic. Ioannina-Greece
Design: Prospective, comparative, interventional and randomized study. (N=200).
Methods: We included 200 eyes that required phacoemulsification and uncomplicated cataractsurgery. Patients were randomly divided into two groups: first group (right eye) included nepafenac 0.3% + dexamethasone 0.1% ophthalmic suspension. Second group (left eye) included dexamethasone 0.1% alone. On thirtieth and ninetieth day after surgery optical coherence tomography was carried out; fluorescein retinal angiography study was performed to confirm the CME.
Results: Mean age of study population was 60.97± 4.91 years. In both groups, presence of flare in the aqueous humor was found in 100% of the patients the first 24 hours. The intraocular pressure average in both groups was 13.04 mmHg ± 2.23. Symptoms associated with the use of NSAID in group 1, 53% of the patients referred sensation of foreign body the first and seventh day post surgery. In group 1, the patients did not develop macular edema unlike group 2 a significantly lower percentage of patients demonstrated Irvine-Gass syndrome within ninetieth day after surgery (two cases without pre-operative risk factors 2%) corroborated with optical coherence tomography and fluorescein retinal angiography.
Conclusion: The combination of nepafenac 0.3% with dexamethasone 0.1% is appropriate for the prophylaxis of Irvine-Gass syndrome, also for the control and the reduction of the postoperative inflammation.
Keywords: Non-steroidal anti-inflammatory; Cystoid macular edema; Optical tomography; Steroids; Nepafenac
Copyright: © 2018 Crisanti S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.